Evidence map›Paper›PMID 25680364›Full record

ArticleBritish journal of anaesthesia2015

Development and characterisation of novel fentanyl-delta opioid receptor antagonist based bivalent ligands.

M F Bird, R S Vardanyan, V J Hruby, G Calò, R Guerrini, S Salvadori, C Trapella, J McDonald, D J Rowbotham, D G Lambert

Open access · bronzeAbstract read
In one paragraph

Article in British journal of anaesthesia, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Novel Pharmacological Nonopioid Therapies in Chronic Pain.Current pain and headache reports · 2018
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

M F BirdDepartment of Cardiovascular Sciences, Division of Anaesthesia, Critical Care and Pain Management, University of Leicester, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, Leicester LE2 7LX, UK.
R S VardanyanDepartment of Chemistry and Biochemistry, University of Arizona, Tucson, AZ 85721, USA.
V J HrubyDepartment of Chemistry and Biochemistry, University of Arizona, Tucson, AZ 85721, USA.
G CalòDepartment of Medical Sciences, Section of Pharmacology, University of Ferrara and Italian Institute of Neuroscience, Ferrara, Italy.
R GuerriniDepartment of Chemical and Pharmaceutical Sciences and LTTA (Laboratorio per le Tecnologie delle Terapie Avanzate), University of Ferrara, Ferrara, Italy.
S SalvadoriDepartment of Chemical and Pharmaceutical Sciences and LTTA (Laboratorio per le Tecnologie delle Terapie Avanzate), University of Ferrara, Ferrara, Italy.
C TrapellaDepartment of Chemical and Pharmaceutical Sciences and LTTA (Laboratorio per le Tecnologie delle Terapie Avanzate), University of Ferrara, Ferrara, Italy.
J McDonaldDepartment of Cardiovascular Sciences, Division of Anaesthesia, Critical Care and Pain Management, University of Leicester, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, Leicester LE2 7LX, UK.
D J RowbothamDepartment of Cardiovascular Sciences, Division of Anaesthesia, Critical Care and Pain Management, University of Leicester, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, Leicester LE2 7LX, UK.
D G LambertDepartment of Cardiovascular Sciences, Division of Anaesthesia, Critical Care and Pain Management, University of Leicester, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, Leicester LE2 7LX, UK dgl3@le.ac.uk.
University of Ferrara · ITLeicester Royal Infirmary · GBUniversity of Arizona · USUniversity of Leicester · GB

Funding

NOVEL NON-PEPTIDE OPIOID LIGANDS FOR PAINR01DA013449 · NIDA · UNIVERSITY OF ARIZONA · PI HRUBY, VICTOR J · 2000 to 2015
$6.8M
PEPTIDOMIMETICS FOR DELTA OPIOID RECEPTORSP01DA008657 · NIDA · UNIVERSITY OF ARIZONA · PI PORRECA, FRANK · 1994 to 1998
–
OPIOID RECEPTOR-SPECIFIC PEPTIDESR01DA004248 · NIDA · UNIVERSITY OF ARIZONA · PI HRUBY, VICTOR J · 1986 to 1999
–
NIDA NIH HHS R01 DA013449
6 · The paper itself

Abstract

backgroundOpioid tolerance is a limiting factor in chronic pain. Delta opioid peptide (DOP)(δ) receptor antagonism has been shown to reduce tolerance. Here, the common clinical mu opioid peptide (MOP)(µ) receptor agonist fentanyl has been linked to the DOP antagonist Dmt-Tic (2',6'-dimethyl-L-tyrosyl-1,2,3,4-tetrahydrisoquinoline-3-carboxylic acid) to create new bivalent compounds.

methodsBinding affinities of bivalents(#9, #10, #11, #12 and #13) were measured in Chinese hamster ovary (CHO) cells expressing recombinant human MOP, DOP, Kappa opioid peptide (KOP)(κ) and nociceptin/orphanin FQ opioid peptide (NOP) receptors. Functional studies, measuring GTPγ[(35)S] or β-arrestin recruitment, were performed in membranes or whole cells respectively expressing MOP and DOP.

resultsThe new bivalents bound to MOP (pKi : #9:7.31; #10:7.58; #11:7.91; #12:7.94; #13:8.03) and DOP (#9:8.03; #10:8.16; #11:8.17; #12:9.67; #13:9.71). In GTPγ[(35)S] functional assays, compounds #9(pEC50:6.74; intrinsic activity:0.05) #10(7.13;0.34) and #11(7.52;0.27) showed weak partial agonist activity at MOP. Compounds #12 and #13, with longer linkers, showed no functional activity at MOP. In antagonist assays at MOP, compounds #9 (pKb:6.87), #10(7.55) #11(7.81) #12(6.91) and #13(7.05) all reversed the effects of fentanyl. At DOP, all compounds showed antagonist affinity (#9:6.85; #10:8.06; #11:8.11; #12:9.42; #13:9.00), reversing the effects of DPDPE ([D-Pen(2,5)]enkephalin). In β-arrestin assays, compared with fentanyl (with response at maximum concentration (RMC):13.62), all compounds showed reduced ability to activate β-arrestin (#9 RMC:1.58; #10:2.72; #11:2.40; #12:1.29; #13:1.58). Compared with fentanyl, the intrinsic activity was: #9:0.12; #10:0.20; #11:0.18; #12:0.09 and #13:0.12.

conclusionsThe addition of a linker between fentanyl and Dmt-Tic did not alter the ability to bind to MOP and DOP, however a substantial loss in MOP functional activity was apparent. This highlights the difficulty in multifunctional opioid development.

Indexed as

AnimalsArrestinsbeta-ArrestinsCHO CellsCricetinaeCricetulusDipeptidesDrug DiscoveryFentanylGuanosine 5'-O-(3-Thiotriphosphate)LigandsReceptors, Opioid, deltaReceptors, Opioid, muTetrahydroisoquinolines2',6'-dimethyltyrosyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acidArrestinsbeta-ArrestinsDipeptidesFentanylGuanosine 5'-O-(3-Thiotriphosphate)LigandsReceptors, Opioid, deltaReceptors, Opioid, muTetrahydroisoquinolinesdelta receptorsfentanylmu receptorsopioidpharmacology - analgesics opioid

Identifiers

PMID25680364
PMCPMC6223790
OpenAlexW2168809910

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.